Valuation: Aradigm Corporation

Market Cap 4.89M 4.35M 4.03M 3.65M 6.86M 463M 6.98M 48.36M 19M 242M 18.32M 17.94M 773M P/E 2016
-0.72x
P/E 2017 -9.3x
Enterprise Value 12.8M 11.39M 10.56M 9.57M 17.98M 1.21B 18.28M 127M 49.77M 634M 48.01M 47.01M 2.02B EV / Sales 2016
73.3x
EV / Sales 2017 7.27x
Free-Float
60.28%
Yield 2016 *
-
Yield 2017 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+6.73% - - 702K
+0.79%-6.16%+49.32%+74.50% 66.34B
-0.02%+6.87%+12.03%+90.96% 52.92B
+0.03%+4.53%+7.14%+72.99% 54.82B
+0.74%+2.75%+26.31%+45.29% 44.09B
+3.87%+10.15%+20.69%+132.73% 43.72B
+7.91%+4.30%+263.91%+602.72% 42.13B
-0.40%+9.85%+17.04%+59.17% 33.96B
-1.30%-0.68%+37.15%+7.04% 26.17B
+0.71%+5.56%+36.55%+26.34% 23.37B
Average +1.23%+5.14%+52.24%+123.53% 38.75B
Weighted average by Cap. +1.43%+4.85%+51.32%+128.40%

Financials

2016 2017
Net sales 195K 174K 161K 146K 274K 18.47M 279K 1.93M 758K 9.67M 731K 716K 30.84M 14.46M 12.88M 11.93M 10.81M 20.32M 1.37B 20.66M 143M 56.25M 717M 54.26M 53.13M 2.29B
Net income -32.94M -29.32M -27.17M -24.62M -46.27M -3.12B -47.05M -326M -128M -1.63B -124M -121M -5.21B -10.7M -9.53M -8.83M -8M -15.04M -1.01B -15.29M -106M -41.63M -531M -40.15M -39.32M -1.69B
Net Debt -9.37M -8.34M -7.73M -7.01M -13.17M -888M -13.39M -92.77M -36.44M -465M -35.15M -34.43M -1.48B 7.91M 7.04M 6.53M 5.92M 11.12M 750M 11.3M 78.33M 30.77M 392M 29.68M 29.07M 1.25B
Logo Aradigm Corporation
Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.
Employees
-
  1. Stock Market
  2. Stocks
  3. ARDMQ Stock